Telaglenastat

DRUG6 trials

Sponsors

Calithera Biosciences, Inc, Massachusetts General Hospital, Washington University School of Medicine, Chan, Stephen, MD, PhD

Conditions

Advanced Cervical CarcinomaCancer of the CervixCardiac SafetyCervical CancerCervix CancerDrug InteractionKEAP1 Gene MutationNFE2L2 Gene Mutation

Phase 1

Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects

CompletedNCT04540965

Calithera Biosciences, IncDrug Interaction

Start: 2020-09-22End: 2020-12-08Updated: 2021-03-09

Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult Subjects

CompletedNCT04607512

Calithera Biosciences, IncCardiac Safety

Start: 2020-10-05End: 2020-12-30Updated: 2021-03-09

TEPH: Telaglenastat Efficacy in Pulmonary Hypertension

Not yet recruitingNCT07223528

Chan, Stephen, MD, PhDPulmonary Hypertension

Start: 2026-02-28End: 2028-09-25Target: 28Updated: 2025-12-11

Phase 2

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

TerminatedNCT04265534

Calithera Biosciences, IncKEAP1 Gene Mutation, NFE2L2 Gene Mutation, Non-Small Cell Lung Cancer +3

Start: 2020-07-24End: 2022-02-09Updated: 2022-09-21

Telaglenastat + Talazoparib In Prostate Cancer

Massachusetts General HospitalProstate Cancer Metastatic

Start: 2021-07-31End: 2021-12-31Target: 30Updated: 2021-04-01

Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer

Not yet recruitingNCT05521997

Washington University School of MedicineAdvanced Cervical Carcinoma, Cancer of the Cervix, Cervical Cancer +1

Start: 2026-07-31End: 2032-10-07Target: 42Updated: 2026-03-13

Related Papers

Metabolic Reprogramming in Cancer: Implications for Immunosuppressive Microenvironment.

2024-10-2728 citations

A phase II randomized study of telaglenastat, a glutaminase (GLS) inhibitor, versus placebo, in combination with pembrolizumab (Pembro) and chemotherapy as first-line treatment for KEAP1/NRF2-mutated non-squamous metastatic non-small cell lung cancer (mNSCLC).

Journal of Clinical Oncology2020-05-206 citations